Palantir’s Latest Contract Is Very Good News for PLTR Stock

InvestorPlace2022-05-06

Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

tigernaut
2022-05-07
tigernaut
👍
Hangen
2022-05-06
Hangen
They need to solve the root of the problem... Stop share dilution and earn profit!
LB881
2022-05-06
LB881
[Strong]
blessed_1
2022-05-06
blessed_1
Thanks
Selivtamil
2022-05-06
Selivtamil
👍
Cheryi
2022-05-06
Cheryi
Ok

Leave a comment

109

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153316571?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-06 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153316571","market":"us","top_or_hot":-1,"title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","media":"InvestorPlace","content":"<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLTR","symbol_name":"Palantir Technologies Inc.","start_time":0,"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","article_id":"1153316571","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","pubTimestamp":1651804011,"columns":[],"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"translate_title":"Palantir的最新合同对PLTR股票来说是一个非常好的消息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLTR":0.9},"content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9066351437,"gmtCreate":1651853117529,"gmtModify":1676534984687,"author":{"id":"3567239827558758","authorId":"3567239827558758","name":"tigernaut","avatar":"https://static.tigerbbs.com/66e331c670eb88443b88c6bdb76224cf","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"idStr":"3567239827558758","authorIdStr":"3567239827558758"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066351437","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","kind":"news","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066323599,"gmtCreate":1651851590411,"gmtModify":1676534984435,"author":{"id":"4087724962016220","authorId":"4087724962016220","name":"Hangen","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":4,"crmLevelSwitch":0,"idStr":"4087724962016220","authorIdStr":"4087724962016220"},"htmlText":"They need to solve the root of the problem... Stop share dilution and earn profit!","listText":"They need to solve the root of the problem... Stop share dilution and earn profit!","text":"They need to solve the root of the problem... Stop share dilution and earn profit!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066323599","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","kind":"news","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066971588,"gmtCreate":1651845429144,"gmtModify":1676534982467,"author":{"id":"4099373918785850","authorId":"4099373918785850","name":"LB881","avatar":"https://static.tigerbbs.com/0c0a14e9e40680c3c7f68874b617b7e9","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":1,"idStr":"4099373918785850","authorIdStr":"4099373918785850"},"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066971588","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","kind":"news","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066074889,"gmtCreate":1651829903641,"gmtModify":1676534979811,"author":{"id":"4112410321254552","authorId":"4112410321254552","name":"blessed_1","avatar":"https://community-static.tradeup.com/news/71622697830d9517eb67a61917d8a95f","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"idStr":"4112410321254552","authorIdStr":"4112410321254552"},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066074889","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","kind":"news","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066034816,"gmtCreate":1651817665335,"gmtModify":1676534977510,"author":{"id":"4113984386762092","authorId":"4113984386762092","name":"Selivtamil","avatar":"https://community-static.tradeup.com/news/9484f4baf16444c5b51ba635248b013d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4113984386762092","authorIdStr":"4113984386762092"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066034816","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","kind":"news","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":616507883,"gmtCreate":1651815812642,"gmtModify":1676533068493,"author":{"id":"3568940106394782","authorId":"3568940106394782","name":"Cheryi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568940106394782","authorIdStr":"3568940106394782"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/616507883","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","kind":"news","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":109,"commentSize":22,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153316571"}